SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Gregory B. Braca, a seasoned financial executive with 40+ years of experience and former president and CEO of TD Bank, has been appointed to Mid Penn Bancorp's Board of Directors effective September 16, 2026, with assignment to the Audit, Compensation, and Risk Committees.
View raw filing on EDGAR →The filing discloses the appointment of Gael Touya as a director effective September 1, 2026, following his appointment as President and Chief Executive Officer (previously disclosed on March 17, 2026). The principal action is Touya taking on the director role, making this an executive appointment. This is material as it involves a change in board composition and reflects the CEO succession that occurred on the same date.
View raw filing on EDGAR →The 6-K discloses the appointment of Yaron Eldad as Chief Financial Officer of Freightos Limited, effective September 1, 2026. The filing provides detailed background on his prior CFO roles at Evogene Ltd. and Yamba Group International, Ltd., as well as his educational credentials and current board service. Appointment of a CFO is a material executive appointment that would affect a reasonable investor's assessment of the registrant's leadership and financial management.
View raw filing on EDGAR →An Nuyttens has been appointed President of Mohawk's Flooring Rest of the World segment, effective mid-October 2026. The appointment emphasizes her 30+ years of international leadership experience and the strategic importance of this segment to the company's long-term growth.
View raw filing on EDGAR →Søren Steenberg Jensen assumed the role of Chief Executive Officer on 1 September 2026, succeeding Mikael Øpstun Skov. The company stated the appointment will not change strategy or operating mode.
View raw filing on EDGAR →Mikael Øpstun Skov was appointed as a Director of Hafnia Limited, effective from the Extraordinary General Meeting on 23 September 2026, following his departure as Chief Executive Officer. The Nomination Committee emphasized his instrumental role in establishing the Company's strategic direction and extensive institutional knowledge.
View raw filing on EDGAR →The Board of Directors appointed Zane Nielsen as Chief Accounting Officer and Corporate Controller effective September 1, 2026, replacing Richard Hoffman in the principal accounting officer role. This is a material executive appointment to a key financial leadership position, supported by detailed biographical information and compensation terms ($350,000 base salary, 50% bonus target, 60% LTI target).
View raw filing on EDGAR →Marc Elia, the Company's Chairman, was appointed as Chief Executive Officer effective August 30, 2026, assuming the principal executive officer role previously held by William Duke, Jr. The appointment includes compensatory arrangements including a base salary of $750,000, target bonus of 70%, stock option grant of 10.7 million shares, and sign-on bonus of $500,000.
View raw filing on EDGAR →The 6-K announces the appointment of Andreas Tolpeit as Chief Financial Officer and member of the executive committee, effective September 1, 2026. While the filing also mentions the departure of Jany Fruytier as CFO, the principal disclosed action is Tolpeit's appointment to a named executive officer role. CFO appointments are material to investors as they affect financial oversight and strategy execution.
View raw filing on EDGAR →Robert Ragusa was appointed to the Board of Directors effective September 1, 2026, and simultaneously appointed to three Board committees (Audit, Compensation, and Nominating and Corporate Governance). The disclosure centers on the appointment action itself, with compensation details provided as a secondary matter under the Non-Employee Director Compensation Policy. Board appointments are material governance events affecting the registrant's leadership structure.
View raw filing on EDGAR →The filing discloses multiple executive leadership changes effective September 1, 2026: M. Sean Covey's transition to Chief Product Officer (a promotion from President, Education Division), John Buchanan's appointment as Executive Vice President, Education (new hire), and Adam Sherman's appointment to succeed Colleen Dom as Executive Vice President, Operations (effective June 1, 2027). While the section also includes Colleen Dom's retirement announcement, the primary focus and most material event is the appointment of executives to key leadership roles, particularly the new Chief Product Officer position and the external hire of an EVP. These changes to senior management structure are material to investors assessing the company's leadership continuity and strategic direction.
View raw filing on EDGAR →The 6-K announces the appointment of Mr. Xiaohui Li as co-executive officer of Jianzhi Education Technology Group Company Limited, effective September 1, 2026. The disclosure provides his background, prior roles at Zhiyi Eastern Securities and Shenzhen Hongying Capital Management, and educational credentials. This is a clear executive appointment that would affect a reasonable investor's assessment of the company's leadership and governance.
View raw filing on EDGAR →Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S. as Chief Medical Officer, effective September 1, 2026. Dr. Charlton brings extensive experience in rare disease and pediatric drug development and will lead the company's planned SOTERIA Phase 2 trial initiation in Q4 2026, making this a material appointment for a clinical-stage biotech company on the eve of a pivotal trial launch.
View raw filing on EDGAR →Greenlight Capital Re appointed John Welch as an independent director effective September 1, 2026, and simultaneously appointed him to three board committees (Audit, Compensation, and Underwriting). The company also elected Ariel Warszawski as a director at its July 28, 2026 Annual General Meeting. Both appointments strengthen the board's governance and oversight capabilities.
View raw filing on EDGAR →The filing discloses two executive changes: the retirement of J. Stanley Fredrick as Chairman and Board member effective September 1, 2026, and the appointment of Robert Toth as Chairman effective the same date. While both a departure and appointment occur, the principal disclosed action centers on Toth's appointment to the Chairman role, which is the forward-looking governance change. The filing emphasizes Toth's qualifications, prior board service, and compensation structure as Chairman, making the appointment the salient event. Fredrick's retirement is presented as context for the transition.
View raw filing on EDGAR →James Bligh was appointed Chief Executive Officer effective August 31, 2026, with an employment agreement providing $600,000 annual base salary and 50% target bonus. While the section also discloses Dr. Andrew Regan's simultaneous resignation as CEO, the principal disclosed action centers on Bligh's appointment to the chief executive role, making exec_appointment the most salient classification.
View raw filing on EDGAR →The filing discloses the appointment of two key executives: Josua Oosthuizen as CEO (effective July 31, 2026) and Pieter Scholtz as CFO (effective August 8, 2026), both under two-year employment agreements with specified compensation. While Item 5.02 also covers compensatory arrangements, the principal disclosed action centers on the appointment of these officers to new roles, particularly the CEO appointment which is material to investor assessment of company leadership and strategy execution.
View raw filing on EDGAR →Dr. Kim Reid was appointed as a director and audit committee member, while John Bientjes resigned as director and audit committee chair, and Davis Fynn was elevated to audit committee chair. The filing centers on Dr. Reid's appointment and her specialized scientific and governance expertise.
View raw filing on EDGAR →The filing discloses both the resignation of Co-CEO and Chairman Sheng-Yih Chang (effective September 1, 2026) and the appointment of Kewei Huang as CEO and Chairman (also effective September 1, 2026). While both events occur, the appointment is the principal forward-looking action and receives more substantive disclosure, including details of the Executive Employment Agreement with $60,000 annual base compensation. The appointment of a new CEO and Chairman to lead the company is material to investors.
View raw filing on EDGAR →The 6-K discloses the appointment of Ms. Yue Zhuo as Chief Financial Officer effective September 1, 2026, following the resignation of Mr. Chaowei Yan on August 31, 2026. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite role. The disclosure includes Ms. Zhuo's background, qualifications, and tenure at the Company, consistent with exec_appointment guidance. CFO changes are material to investors assessing financial reporting and governance.
View raw filing on EDGAR →The filing discloses the appointment of four new independent directors (Richard O'Brien, Marcelo Godoy, Josh Olmsted, and Blake Rhodes) to Hycroft's Board, effective September 1, 2026, expanding the Board from five to nine directors. O'Brien was also appointed Lead Independent Director. This is a material governance event affecting board composition and leadership structure, with the appointees bringing substantial industry experience from major mining companies (Newmont, AngloGold Ashanti, Freeport-McMoRan).
View raw filing on EDGAR →The filing discloses the appointment of Liu Ming Hui as Chairman and Liu Ming Xing as Chief Executive Officer of HWH International Inc., effective September 1, 2026. While Chan Heng Fai's resignation as Chairman and CEO is also mentioned, the primary focus and substance of the disclosure centers on the appointment of the two new executives to lead the company. Both appointees are newly appointed board members (as of August 10, 2026) and bring significant international business experience from China Gas Holdings Limited, a major Hong Kong-listed company. This executive leadership transition is material to investors as it represents a fundamental change in the company's top management.
View raw filing on EDGAR →Nick Konat, current president and COO, was appointed as Chief Executive Officer and Board member effective January 4, 2027, following a comprehensive Board succession process. Jack Sinclair transitioned to Executive Chairman. The appointment represents a material leadership change at the company's highest level.
View raw filing on EDGAR →Quantum Corporation appointed Hiral A. Patel as Chief Accounting Officer and Principal Accounting Officer, effective September 1, 2026. Ms. Patel's compensation package includes a base salary of $335,000, a 50% target bonus, and 50,000 restricted stock units.
View raw filing on EDGAR →AstraZeneca announced the appointment of Wan Ling Martello as a Non-Executive Director effective 1 September 2026, with membership on the Audit Committee. This is a clear executive appointment to the board of a major pharmaceutical company, and the disclosure includes biographical details and a statement from the Chair endorsing her qualifications. Board appointments at large-cap public companies are material to investors assessing governance and oversight.
View raw filing on EDGAR →Lisa Wolf was appointed to the expanded roles of President and Chief Operating Officer in addition to her existing Chief Financial Officer role, and Jared Malbin and Thomas Jensen were appointed as directors to the Board, effective August 27, 2026, following the departure of former CEO Michael K. Handley.
View raw filing on EDGAR →The Board appointed Stephan May as a director effective August 27, 2026, and appointed him to the Compensation and Human Resources Committee. The appointment is material as it involves a director-level position designated by major shareholder Siemens Industry under a Stockholders Agreement and fills a vacancy created by a prior resignation.
View raw filing on EDGAR →The filing discloses both a departure (Mark Klingensmith resigning as CFO and Treasurer effective September 1, 2026) and an appointment (Siddhartha Chowdhury appointed to the same roles on the same date). While both events occur, the appointment is the principal forward-looking disclosure—the Board's action to fill the vacancy with a named successor whose qualifications and background are detailed. The appointment of a CFO is material to investors assessing the company's financial leadership and governance.
View raw filing on EDGAR →The Board appointed Byron Pollan to the newly created position of Senior Vice President and Deputy Chief Financial Officer effective September 1, 2026, with a planned succession to Chief Financial Officer in mid-2027 upon Ron Copher's retirement.
View raw filing on EDGAR →Martin Franc has been appointed as Senior Managing Director and Head of Asia Pacific, succeeding Andrew Lo who will retire effective March 31, 2027, after 32 years with Invesco. This represents material succession planning for a key executive position overseeing a significant regional business.
View raw filing on EDGAR →The media release announces the appointment of three non-executive directors—Stephan B. Tanda, Denise C. Johnson, and Robert Schuchna—to the combined company Board upon completion of the pending AkzoNobel-Axalta merger. The disclosure explicitly states these individuals "have agreed to serve as non-executive Directors of the combined company" and details their qualifications and roles. This is a governance event involving executive/director appointments material to the merged entity's leadership structure.
View raw filing on EDGAR →The filing discloses the appointment of Quentin Blackford, an experienced healthcare executive (currently CEO of iRhythm Technologies), to Align Technology's Board of Directors effective August 27, 2026. While the section also mentions Andrea L. Saia's resignation, the principal disclosed action centers on the appointment of a new director. Blackford's appointment is material as it represents a change in board composition and governance at a large-cap medical device company, and his background in healthcare and digital innovation is relevant to investor assessment of board quality and strategic direction.
View raw filing on EDGAR →Wendy Reynolds-Dobbs was appointed to serve as Senior Vice President & Chief Human Resources Officer, effective September 14, 2026. This is a named executive appointment to a C-suite role. While the filing also mentions Jed Milstein's transition out of the same role, the principal disclosed action centers on Reynolds-Dobbs taking the position, making this an exec_appointment rather than a departure.
View raw filing on EDGAR →The press release announces the appointment of Chris Benecchi as Chief Operating Officer of Inventiva, effective August 31, 2026. This is a clear executive appointment of a named officer to a C-suite role. The appointment is material because it occurs at a critical juncture—as the company approaches Phase 3 topline results for its lead candidate lanifibranor (expected Q4 2026) and prepares for potential commercialization in 2028—and Benecchi brings 30 years of biopharmaceutical leadership with direct experience in launch readiness and commercial operations.
View raw filing on EDGAR →The exhibit announces the appointment of Yoav Har-Even as Chairperson of the Board of Directors, effective immediately. While the prior Chairperson Amichai Steimberg stepped down, the principal disclosed action is Har-Even's appointment to the chair role. His extensive background as former President & CEO of Rafael Advanced Defense Systems and retired IDF Major General, combined with the Board's stated rationale that his appointment "reflects the strategic weight defense and security now carry for Innoviz," makes this a material governance change affecting board leadership at a public company.
View raw filing on EDGAR →Charles A. "Chuck" Parcher has assumed the role of President and Chief Executive Officer of Civista Bancshares, Inc. effective August 31, 2026, completing a previously announced leadership transition. While Dennis Shaffer's retirement as President and CEO is also disclosed, the principal action disclosed is Parcher's appointment to the CEO role, making this an exec_appointment event. The appointment of a new CEO is material to investors as it represents a significant change in leadership and strategic direction.
View raw filing on EDGAR →The filing discloses the Board's appointment of Dominic E. Dragisich as President and CEO effective August 31, 2026, and his concurrent appointment as a director. While the filing also mentions Patrick S. Pacious's resignation as former President and CEO, the principal disclosed action centers on Dragisich's appointment to the top executive role and the Board. The compensation details and amended severance agreement are ancillary to the core appointment event. This is material as it represents a permanent leadership transition for the company's chief executive.
View raw filing on EDGAR →The filing discloses the appointment of Brian J. Comstock as Chief Executive Officer and President of Greenbrier, effective January 6, 2027, following the Board's succession planning process. While the section also mentions Lorie Tekorius's retirement, the principal action disclosed is Comstock's appointment to the CEO role, which is the forward-looking material event. The filing emphasizes the Board's deliberate succession process and Comstock's qualifications and experience, making the appointment the salient event.
View raw filing on EDGAR →The Board appointed Kristopher R. Westbrooks as President and Chief Executive Officer and Board member effective January 1, 2027, succeeding Michael S. Williams who is retiring effective December 31, 2026. The filing discloses detailed compensation arrangements for Westbrooks in his new role.
View raw filing on EDGAR →The disclosure centers on the appointment of Tommy E. Darby as Vice President, Chief Accounting Officer of Westlake Corporation, effective immediately on August 31, 2026. While the filing also includes compensatory details (salary of $440,000, bonus targets, and a $135,000 sign-on RSU award), the principal action is the appointment of a named executive officer to a key financial leadership role. The transition of Jeffrey A. Holy to a different position is secondary to Darby's appointment. This is material as it involves a change in the chief accounting officer position, a critical role for financial reporting and internal controls.
View raw filing on EDGAR →Tommy E. Darby was appointed to the position of Vice President, Chief Accounting Officer of Westlake Chemical Partners GP LLC (the general partner) effective immediately on August 31, 2026, and concurrently to the same role at Westlake Corporation. This is a material executive appointment to a senior financial officer position responsible for accounting oversight. While Jeffrey A. Holy's transition to a different role is also mentioned, the principal disclosed action centers on Darby's appointment to the Chief Accounting Officer position.
View raw filing on EDGAR →Kohl's appointed Ryan M. Waymire as Chief Merchandising Officer effective September 28, 2026, reporting directly to CEO Michael J. Bender. Waymire brings 25 years of retail leadership experience from Walmart, Amazon, Target, and other major retailers. The appointment was announced via press release and represents a significant governance event affecting leadership continuity and strategic direction.
View raw filing on EDGAR →On August 25, 2026, four independent directors—Verender S. Badial, Christopher Staral, Dr. Arjun Goyal, and Dr. Jonathon Kluft—were appointed to the Board and simultaneously appointed to chair or serve on the Audit, Compensation, and Nominating and Corporate Governance Committees in connection with the IPO.
View raw filing on EDGAR →Morris Berger was appointed as Chief Executive Officer effective October 1, 2026, with Jonathan Reich transitioning from CEO to President and Chief Operating Officer. The appointment includes a $450,000 base salary, $50,000 signing bonus, and equity options equal to 3% of outstanding shares, supported by a $7.5 million insider investment by Berger.
View raw filing on EDGAR →The material event disclosed is the appointment of independent director Lee McIntire as Chief Executive Officer, effective August 11, 2026. While the Item 5.08 section addresses routine shareholder meeting logistics and nomination deadlines, the substantive disclosure in Item 8.01 (Other Events) centers on McIntire's appointment to the CEO role—a senior executive appointment that would materially affect investor assessment of the company's leadership. The associated Audit Committee changes (McIntire's resignation and Stein's appointment) are secondary governance adjustments flowing from the CEO appointment.
View raw filing on EDGAR →The filing discloses both the departure of CEO Katharyn Field and the appointment of Shahin Behroyan as Chief Executive Officer, effective August 26, 2026. While both events occurred, the principal disclosed action centers on the appointment of a new CEO with detailed background, qualifications, and a new Independent Contractor Agreement ($350,000 annual fee). The appointment of a new chief executive is material to investors and represents the salient event, though the departure is also disclosed.
View raw filing on EDGAR →The announcement discloses two executive appointments: Ms. Diana Marcela Acero Rojas as Acting Corporate Vice President of Science, Technology and Innovation (effective September 1, 2026) and Mr. Henryk Manuel Porras Villamil as Acting Executive Vice President of Energy Transition (effective August 31, 2026). While both are interim/acting roles, they represent formal Board-adopted resolutions elevating individuals to senior management positions. The disclosure also mentions departures (Mr. Moreno ceasing his role and Mr. Gómez Cabarcas taking statutory leave), but the principal disclosed action is the appointment of two executives to Vice President-level roles, making exec_appointment the primary classification. These are material changes to senior leadership at a major integrated energy company.
View raw filing on EDGAR →The filing discloses the appointment of two directors, James A. Greer and Oscar K. Brown, to Primoris' Board of Directors effective October 1, 2026, with the Board voting to increase authorized directors to ten members. This is a clear executive appointment event under Item 5.02, with both appointees bringing substantial industry experience (Greer with 40+ years in energy delivery and prior COO role at Oncor; Brown with 25+ years in energy and current CEO of Western Midstream). The appointment of experienced directors to a public company board is material to investors' assessment of governance and strategic direction.
View raw filing on EDGAR →Michael Grasher was appointed as Chief Financial Officer of Teladoc Health effective August 31, 2026, replacing interim CFO Charles Divita III. The appointment includes a $550,000 base salary, $500,000 sign-on bonus, and $3,000,000 in equity awards, reflecting his extensive financial leadership experience including prior CFO roles at AMERISAFE, Fortegra, and IFG Companies.
View raw filing on EDGAR →Sean Valashinas was appointed as acting Chief Financial Officer effective immediately, following Willard Station's medical leave of absence from the CFO role.
View raw filing on EDGAR →